IL143481A0 - Glp-1 analogues - Google Patents
Glp-1 analoguesInfo
- Publication number
- IL143481A0 IL143481A0 IL14348199A IL14348199A IL143481A0 IL 143481 A0 IL143481 A0 IL 143481A0 IL 14348199 A IL14348199 A IL 14348199A IL 14348199 A IL14348199 A IL 14348199A IL 143481 A0 IL143481 A0 IL 143481A0
- Authority
- IL
- Israel
- Prior art keywords
- analogues
- glp
- peptide
- glucagon
- pharmaceutically
- Prior art date
Links
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11118698P | 1998-12-07 | 1998-12-07 | |
| US20683398A | 1998-12-07 | 1998-12-07 | |
| PCT/US1999/028929 WO2000034332A1 (en) | 1998-12-07 | 1999-12-07 | Glp-1 analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL143481A0 true IL143481A0 (en) | 2002-04-21 |
Family
ID=26808707
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14348199A IL143481A0 (en) | 1998-12-07 | 1999-12-07 | Glp-1 analogues |
| IL143481A IL143481A (en) | 1998-12-07 | 2001-05-31 | Glp-1 analogues |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL143481A IL143481A (en) | 1998-12-07 | 2001-05-31 | Glp-1 analogues |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7368427B1 (cs) |
| EP (2) | EP1992641A3 (cs) |
| JP (3) | JP2002538081A (cs) |
| KR (1) | KR100458748B1 (cs) |
| CN (2) | CN100334109C (cs) |
| AT (1) | ATE394423T1 (cs) |
| AU (1) | AU770609B2 (cs) |
| BR (1) | BR9916027A (cs) |
| CA (1) | CA2352573C (cs) |
| CZ (2) | CZ303399B6 (cs) |
| DE (1) | DE69938669D1 (cs) |
| DK (1) | DK1137666T5 (cs) |
| ES (1) | ES2302390T3 (cs) |
| HU (1) | HUP0104579A3 (cs) |
| IL (2) | IL143481A0 (cs) |
| NO (2) | NO330293B1 (cs) |
| PL (3) | PL393611A1 (cs) |
| PT (1) | PT1137666E (cs) |
| RU (1) | RU2208015C2 (cs) |
| TW (2) | TWI262925B (cs) |
| WO (1) | WO2000034332A1 (cs) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ303399B6 (cs) | 1998-12-07 | 2012-08-29 | Ipsen Pharma S.A.S. | Peptidový analog GLP-1 a farmaceutický prostredek jej obsahující |
| BR9915961A (pt) | 1998-12-07 | 2001-08-21 | Sod Conseils Rech Applic | Análogos de glp-1 |
| AU2001279526A1 (en) * | 2000-08-02 | 2002-02-13 | Theratechnologies Inc. | Modified peptides with increased potency |
| DE60134251D1 (de) * | 2000-09-18 | 2008-07-10 | Sanos Bioscience As | Verwendung von glp-2-peptiden |
| US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
| CA2395165C (en) * | 2000-10-20 | 2012-05-22 | Mario Ehlers | Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide |
| EP1346722B1 (en) | 2000-12-01 | 2008-12-10 | Takeda Pharmaceutical Company Limited | Method for producing preparation containing bioactive substance |
| EP2022505B1 (en) | 2001-07-31 | 2011-12-14 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | GLP-1, exendin-4, peptide analogs and uses thereof |
| AU2012202081B2 (en) * | 2001-07-31 | 2014-09-25 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GLP-1 Exendin-4 peptide analogs and uses thereof |
| GEP20063908B (en) * | 2001-10-18 | 2006-08-25 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| US7238671B2 (en) | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| US7589058B2 (en) * | 2002-07-23 | 2009-09-15 | Ipsen Pharma, S.A.S. | Ghrelin analogs |
| EP1583549A4 (en) * | 2003-01-17 | 2006-10-04 | Sod Conseils Rech Applic | YY PEPTIDE ANALOGS |
| CN1750842A (zh) * | 2003-02-19 | 2006-03-22 | 研究及应用科学协会股份有限公司 | Glp－1的类似物 |
| EP1609855A4 (en) * | 2003-03-28 | 2008-06-11 | Nat Inst Of Agrobio Sciences | METHOD FOR PRODUCING A VEGETABLE STORAGE ORGANIZATION HIGH PRODUCTION OF RECOMBINANT PROTEIN AND NEW RECOMBINANT PROTEIN |
| US7094800B2 (en) | 2003-07-25 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Cyanopyrrolidides, process for their preparation and their use as medicaments |
| US7008957B2 (en) | 2003-07-25 | 2006-03-07 | Sanofi-Aventis Deutschland Gmbh | Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments |
| US7094794B2 (en) | 2003-07-28 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use |
| DE10335092B3 (de) | 2003-08-01 | 2005-02-03 | Aventis Pharma Deutschland Gmbh | Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung |
| JP2007514752A (ja) * | 2003-12-16 | 2007-06-07 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Ｇｌｐ−１医薬組成物 |
| CA2551039C (en) * | 2003-12-16 | 2013-01-29 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R | Analogues of glp-1 |
| JP2007537149A (ja) * | 2004-01-08 | 2007-12-20 | セラテクノロジーズ インコーポレイテッド | 長時間作用性のグルカゴン様ペプチド−１類似体 |
| US7534763B2 (en) | 2004-07-02 | 2009-05-19 | Bristol-Myers Squibb Company | Sustained release GLP-1 receptor modulators |
| TW200611704A (en) | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
| BRPI0612069A2 (pt) * | 2005-06-13 | 2009-01-20 | Imp Innovations Ltd | compostos e seus efeitos sobre o comportamento de alimentaÇço |
| EP1943275B1 (en) * | 2005-11-01 | 2010-06-16 | Activotec SPP Limited | Insulinotropic compounds and uses thereof |
| EP2364735A3 (en) | 2005-12-16 | 2012-04-11 | Nektar Therapeutics | Branched PEG conjugates of GLP-1 |
| WO2007124461A2 (en) | 2006-04-20 | 2007-11-01 | Amgen Inc. | Glp-1 compounds |
| US20100022457A1 (en) | 2006-05-26 | 2010-01-28 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
| CA2674354A1 (en) * | 2007-01-05 | 2008-07-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
| WO2009035540A2 (en) * | 2007-09-07 | 2009-03-19 | Ipsen Pharma S.A.S. | Analogues of exendin-4 and exendin-3 |
| WO2009155257A1 (en) * | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers |
| RU2011131714A (ru) * | 2008-12-29 | 2013-02-10 | Панацеа Биотек Лтд. | Аналоги glp-1 и их использования |
| KR20130102470A (ko) * | 2010-06-24 | 2013-09-17 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그 |
| WO2012054822A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Pharmacologically active polymer-glp-1 conjugates |
| WO2012054861A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Glp-1 polymer conjugates having a releasable linkage |
| DK2713722T3 (en) | 2011-05-31 | 2017-07-03 | Celgene Int Ii Sarl | Newly known GLP-1 receptor stabilizers and modulators |
| MX365923B (es) | 2011-12-12 | 2019-06-20 | Celgene Int Ii Sarl | Derivados de acido carboxilico que comprenden cuatro ciclos, que actuan como moduladores del receptor del peptido 1 similar al glucagon (glp-1) para terapia de enfermedades como la diabetes. |
| CN102584982B (zh) * | 2012-02-10 | 2014-02-05 | 深圳翰宇药业股份有限公司 | 一种纯化固相合成利拉鲁肽粗肽的方法 |
| US20150157619A1 (en) | 2012-07-10 | 2015-06-11 | Takeda Pharmaceutical Company Limited | Pharmaceutical preparation for injection |
| TN2015000451A1 (en) * | 2013-05-28 | 2017-04-06 | Takeda Pharmaceuticals Co | Peptide compound |
| CN103285379A (zh) * | 2013-06-09 | 2013-09-11 | 南方医科大学 | Glp-1用于制备预防与治疗2型糖尿病大血管并发症的药物的用途 |
| HK1222176A1 (zh) | 2013-06-11 | 2017-06-23 | Receptos Llc | 新型glp-1受體調節劑 |
| AU2015292356B2 (en) | 2014-07-25 | 2020-02-06 | Receptos Llc | Novel GLP-1 receptor modulators |
| JP2018012644A (ja) * | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
| US9795613B2 (en) | 2014-12-10 | 2017-10-24 | Celgene International Ii Sàrl | GLP-1 receptor modulators |
| JP2018507914A (ja) | 2015-03-09 | 2018-03-22 | インテクリン・セラピューティクス・インコーポレイテッド | 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法 |
| UA127495C2 (uk) | 2015-12-23 | 2023-09-13 | Амджен Інк. | Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить |
| CA3009506A1 (en) | 2015-12-23 | 2017-06-29 | The Johns Hopkins University | Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions |
| US10501516B2 (en) | 2016-05-24 | 2019-12-10 | Takeda Pharmaceutical Company Limited | Peptide compound |
| CN109715185A (zh) * | 2016-06-02 | 2019-05-03 | 印第安纳大学研究及科技有限公司 | 水溶性且化学稳定的胰高血糖素肽 |
| JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
| CN110996951A (zh) | 2017-04-03 | 2020-04-10 | 科赫罗斯生物科学股份有限公司 | 治疗进行性核上性麻痹的PPARγ激动剂 |
| CN109942696A (zh) * | 2017-12-21 | 2019-06-28 | 中国药科大学 | 长效化胰高血糖素样肽－1（glp－1）类似物及其应用 |
| CN116970062B (zh) * | 2022-04-29 | 2024-04-09 | 南京知和医药科技有限公司 | 一种超长效glp-1多肽衍生物及其制备方法和用途 |
| WO2023246928A1 (zh) | 2022-06-23 | 2023-12-28 | 广州银诺医药集团股份有限公司 | 一种改进的glp-1受体激动剂的融合蛋白和应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1539498A (en) | 1925-05-26 | And fifteen | ||
| US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| DK0511978T3 (da) * | 1990-01-24 | 1994-08-01 | Upjohn Co | Fremgangsmåde til rensning af rekombinante polypeptider |
| JP3262329B2 (ja) | 1990-01-24 | 2002-03-04 | アイ． バックレイ，ダグラス | 糖尿病治療に有用なｇｌｐ―１アナログ |
| DK36392D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
| BR9306551A (pt) * | 1992-06-15 | 1998-09-15 | Pfizer | Derivados de peptídeo do tipo glucagona e de insulinotropina |
| US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
| WO1997029180A1 (en) * | 1996-02-06 | 1997-08-14 | Eli Lilly And Company | Diabetes therapy |
| US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| CA2264243C (en) * | 1996-08-30 | 2004-10-05 | Novo Nordisk A/S | Glp-1 derivatives |
| US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| AU6586298A (en) * | 1997-03-31 | 1998-10-22 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
| WO1999043705A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | N-terminally truncated glp-1 derivatives |
| FR2777283B1 (fr) | 1998-04-10 | 2000-11-24 | Adir | Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6720407B1 (en) | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
| BR9915961A (pt) | 1998-12-07 | 2001-08-21 | Sod Conseils Rech Applic | Análogos de glp-1 |
| CZ303399B6 (cs) | 1998-12-07 | 2012-08-29 | Ipsen Pharma S.A.S. | Peptidový analog GLP-1 a farmaceutický prostredek jej obsahující |
| EP1239871A1 (en) | 1999-11-12 | 2002-09-18 | Novo Nordisk A/S | Use of glp-1 agonists for the inhibition of beta cell degeneration |
| CN114612953A (zh) | 2020-12-09 | 2022-06-10 | 佳能株式会社 | 对象识别模型的训练方法及装置 |
-
1999
- 1999-12-07 CZ CZ20120110A patent/CZ303399B6/cs not_active IP Right Cessation
- 1999-12-07 DE DE69938669T patent/DE69938669D1/de not_active Expired - Lifetime
- 1999-12-07 JP JP2000586774A patent/JP2002538081A/ja active Pending
- 1999-12-07 CN CNB998141852A patent/CN100334109C/zh not_active Expired - Fee Related
- 1999-12-07 ES ES99960657T patent/ES2302390T3/es not_active Expired - Lifetime
- 1999-12-07 US US09/856,676 patent/US7368427B1/en not_active Expired - Fee Related
- 1999-12-07 CA CA2352573A patent/CA2352573C/en not_active Expired - Fee Related
- 1999-12-07 EP EP08005960A patent/EP1992641A3/en not_active Withdrawn
- 1999-12-07 IL IL14348199A patent/IL143481A0/xx unknown
- 1999-12-07 HU HU0104579A patent/HUP0104579A3/hu unknown
- 1999-12-07 PT PT99960657T patent/PT1137666E/pt unknown
- 1999-12-07 PL PL393611A patent/PL393611A1/pl unknown
- 1999-12-07 CN CN2007101410499A patent/CN101108878B/zh not_active Expired - Fee Related
- 1999-12-07 PL PL385112A patent/PL208751B1/pl unknown
- 1999-12-07 DK DK99960657T patent/DK1137666T5/da active
- 1999-12-07 WO PCT/US1999/028929 patent/WO2000034332A1/en active Application Filing
- 1999-12-07 AT AT99960657T patent/ATE394423T1/de active
- 1999-12-07 BR BR9916027-7A patent/BR9916027A/pt not_active IP Right Cessation
- 1999-12-07 CZ CZ20011895A patent/CZ303120B6/cs not_active IP Right Cessation
- 1999-12-07 EP EP99960657A patent/EP1137666B9/en not_active Expired - Lifetime
- 1999-12-07 PL PL349609A patent/PL205713B1/pl unknown
- 1999-12-07 KR KR10-2001-7007050A patent/KR100458748B1/ko not_active Expired - Fee Related
- 1999-12-07 RU RU2001118839/04A patent/RU2208015C2/ru not_active IP Right Cessation
- 1999-12-07 AU AU17512/00A patent/AU770609B2/en not_active Ceased
-
2000
- 2000-01-07 TW TW088121393A patent/TWI262925B/zh not_active IP Right Cessation
- 2000-01-07 TW TW095106593A patent/TWI339208B/zh not_active IP Right Cessation
-
2001
- 2001-05-31 IL IL143481A patent/IL143481A/en not_active IP Right Cessation
- 2001-06-06 NO NO20012787A patent/NO330293B1/no not_active IP Right Cessation
-
2005
- 2005-10-13 JP JP2005298418A patent/JP2006077022A/ja active Pending
-
2008
- 2008-05-06 US US12/115,976 patent/US20090149378A1/en not_active Abandoned
-
2009
- 2009-08-14 JP JP2009188046A patent/JP2010001301A/ja active Pending
-
2010
- 2010-03-04 NO NO20100307A patent/NO20100307L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL143481A0 (en) | Glp-1 analogues | |
| PL349468A1 (en) | Analogues of glp-1 | |
| EA200300026A1 (ru) | Аналоги глюкагоноподобного пептида-1 | |
| WO2004074315A3 (en) | Analogues of glp-1 | |
| WO2003061362A3 (en) | Methods and compositions for treating polycystic ovary syndrome | |
| MXPA04001525A (es) | Analogos de peptido -1 similar al glucagon. | |
| UA35636C2 (uk) | Поліпептид, який має активність легеневої поверхнево-активної речовини, та фармацевтична композиція для лікування респіраторного дистрес-синдрому у ссавців | |
| CO5090908A1 (es) | Procedimiento para administrar peptidos insulinotropicos | |
| ATE177757T1 (de) | Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17 | |
| WO2007005738A3 (en) | Glp-1 pharmaceutical compositions | |
| ATE169225T1 (de) | Anwendung von urodilatin bei lungen- und bronchialerkrankungen | |
| EP2210900A3 (en) | Analogues of GLP-1 | |
| EP1359159A3 (en) | Analogues of GLP-1 | |
| UA88862C2 (en) | Glucagon-like peptide-1 analogs |